1. Cibas, ES, & Ducatman, BS. (2009). Cytology: Diagnostic principles and clinical correlates. Philadelphia, PA: Saunders/Elsevier.
  2. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
  3. Yachida, S, Vakiani, E, White, C, et al. Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2012;36(2):173-184. doi: 10.1097/PAS.0b013e3182417d36.
  4. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199-1203. doi:10.1126/science.1200609.
  5. Scarpa, A. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543: 65–71. doi: 10.1038/nature21063.
  6. Chan, CS, Laddha, SV, Lewis, PW et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9, 4158 (2018).
  7. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001 Dec;7(12):4115-21. PMID: 11751510.
  8. Kim, H, An, S, Lee, K, et al. Pancreatic high-grade neuroendocrine neoplasms in the Korean population: A multicenter study. Cancer Res Treat. 2020;52(1):263-276. doi: 10.4143/crt.2019.192.
  9. Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40(9):1192-1202. PMID: 27259015
  10. Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72:168–177. doi: 10.1111/his.13408.
  11. Guilmette, JM and Nosé, V. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. Advances in Anatomic Pathology. 2019;26(1):13-30. PMID: 29912000.
  12. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer; 2017. pp. 209–240.
  13. Basturk, O, Yang, Z, Tang, L, et al. The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms. The American Journal of Surgical Pathology. 2015;39(5):683-690. PMID: 25723112.
  14. Siegel, CS, Silva, VWK, Reid, MD, et al. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study. Cancer Cytopathology. 2018;126:326-335. doi: 10.1002/cncy.21982.
  15. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; Other Knowledge Network Members: Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015;22:657-664. doi: 10.1530/ERC-15-0119.